Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 5.9% – Should You Sell?

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) fell 5.9% on Monday . The company traded as low as $18.55 and last traded at $18.71. 908,187 shares were traded during mid-day trading, a decline of 65% from the average session volume of 2,617,507 shares. The stock had previously closed at $19.88.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ARWR. Piper Sandler decreased their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, January 23rd. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. Citigroup decreased their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. Finally, Chardan Capital restated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $43.33.

Arrowhead Pharmaceuticals Price Performance

The stock has a fifty day moving average of $20.88 and a 200 day moving average of $21.68. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -3.73 and a beta of 0.95.

Insider Activity

In other news, insider James C. Hamilton sold 32,729 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $648,688.78. Following the completion of the sale, the insider now directly owns 272,122 shares in the company, valued at $5,393,458.04. The trade was a 10.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director William D. Waddill sold 3,748 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $21.90, for a total transaction of $82,081.20. Following the sale, the director now directly owns 44,125 shares of the company’s stock, valued at $966,337.50. This represents a 7.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 147,432 shares of company stock valued at $2,957,986 in the last ninety days. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of large investors have recently made changes to their positions in ARWR. R Squared Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $38,000. Values First Advisors Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $52,000. Van ECK Associates Corp lifted its holdings in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 1,250 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 788 shares during the period. Finally, KBC Group NV lifted its stake in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares during the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.